

**RECEIVED
CENTRAL FAX CENTER**

OCT 17 2007

PATENT
Docket No. 180.00120101**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Zhao Yi WANG) Group Art Unit: 1647
Serial No.: 10/591,199) Examiner: Shulamith H. Shafer
Confirmation No.: 4302)
Filed: August 30, 2006)
For: ESTROGEN RECEPTORS AND METHODS OF USE

FACSIMILE TRANSMISSION TO THE PTO

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FAX NUMBER: (571) 273-8300
Total Pages (including cover page): 10
Time: 10:53am (Central Time)
(Transmission must be complete by midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: Request for Corrected Filing Receipt (2 pgs.); copy of page 1 of the Filing Receipt (1 pg); copy of previously submitted Application Data Sheet (2 pgs); copy of previously submitted Declaration (3 pgs); and copy of page one of the filed application (1 pg).

X Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueting, Raasch & Gebhardt, P.A.
Customer Number: 26813

October 17, 2007
Date

By: David L. Provence
David L. Provence
Reg. No. 43,022
Direct Dial (612)305-1005

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 17th day of October, 2007, at 10:53am (Central Time).

October 17, 2007
Date

Signature: Deb Schurmann
Name: Deb Schurmann

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

**RECEIVED
CENTRAL FAX CENTER**

PATENT

Docket No. 180.00120101

OCT 17 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zhao Yi WANG)	Group Art Unit:	1647
)		
Serial No.: 10/591,199)	Examiner:	Shulamith H. Shafer
Confirmation No.: 4302)		
)		
Filed: August 30, 2006)		

For: **ESTROGEN RECEPTORS AND METHODS OF USE****REQUEST FOR CORRECTED FILING RECEIPT**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Upon review of the Filing Receipt received from the U.S. Patent and Trademark Office in connection with the above-identified application, the following error was noted.

Under "Domestic Priority data as claimed by applicant " the provisional application number and filing date on the second line is incorrect. Please remove 60/522,067 filed on August 10, 2004 and replace it with 60/552,067, filed on March 10, 2004. A copy of the Filing Receipt with this correction marked is enclosed. Also enclosed is a copy of the previously submitted Application Data Sheet, a copy of the previously submitted Declaration and a copy of the first page of the filed application, all of which show the correct priority data. Applicant respectfully requests a corrected Filing Receipt.

Request for Corrected Filing Receipt

Applicant(s): Zhao Yi Wang

Serial No.: 10/591,199

Confirmation No.: 4302

Filed: August 30, 2006

For: ESTROGEN RECEPTORS AND METHODS OF USE**RECEIVED
CENTRAL FAX CENTER**

Page 2 of 2

OCT 17 2007

If the Examiner has any questions regarding this submission, please contact
Applicant's Representative at the below-listed telephone number.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper
is being transmitted by facsimile in accordance
with 37 CFR §1.6(d) to the Patent and
Trademark Office, addressed to: Mail Stop
Missing Parts, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450, on this
17th day of October, 2007, at
10:53am (Central Time).

By: Deb SchurmanName: Deb Schurman

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone (612)305-1220

Facsimile (612)305-1228

Customer Number 26813

October 17, 2007
Date

By: David L. Provence

David L. Provence

Reg. No. 43,022

Direct Dial (612)305-1005

RECEIVED
CENTRAL FAX CENTER

OCT 17 2007



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
10/591,199	06/13/2007	1646	2240	180.00120101	52	11

26813

MUETING, RAASCH & GEBHARDT, P.A.
P.O. BOX 581415
MINNEAPOLIS, MN 55458

COPY

CONFIRMATION NO. 4302

FILING RECEIPT



OC000000025130325

Date Mailed: 08/01/2007

Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Zhao Yi Wang, Bellevue, NE;

Power of Attorney: The patent practitioners associated with Customer Number 26813.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US05/07857 03/10/2005

which claims benefit of ~~60/522,067 08/10/2004~~

and claims benefit of 60/643,469 01/13/2005

*60/552,067, filed on March 10,
2004*

Foreign Applications

If Required, Foreign Filing License Granted: 07/31/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/591,199**

Projected Publication Date: 11/08/2007

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

RECEIVED

AUG 06 2007

MUETING & RAASCH

APPLICATION DATA SHEET

RECEIVED
CENTRAL FAX CENTER

OCT 17 2007

COPY

APPLICATION INFORMATION

Application Type:: REGULAR
Subject Matter:: UTILITY
CD-ROM or CD-R?: NONE
Sequence Submission?: PAPER
Computer Readable Form (CRF)?:: YES
Number of Copies of CRF:: 1
Title:: ESTROGEN RECEPTORS AND
METHODS OF USE
Attorney Docket Number:: 180.00120101
Total Drawing Sheets:: 26
Licensed US Govt. Agency:: Department of Health and Human
Services
Contract or Grant Numbers:: CA84328

INVENTOR INFORMATION

Applicant Authority Type:: INVENTOR
Primary Citizenship Country:: US
Status:: FULL CAPACITY
Given Name:: Zhao
Middle Name:: Yi
Family Name:: WANG
City of Residence:: Bellevue
State or Province of Residence:: NE
Country of Residence:: US
Street of Mailing Address:: 10005 South 11th Street
City of Mailing Address:: Bellevue
State or Province of Mailing Address:: NE
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 68123

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 26813

REPRESENTATIVE INFORMATION

Representative Customer Number:: 26813

DOMESTIC PRIORITY INFORMATION

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	National Stage of	PCT/US05/007857	03/10/05
PCT/US05/007857	119(e) of	60/552,067	03/10/04
PCT/US05/007857	119(e) of	60/643,469	01/13/05

FOREIGN PRIORITY INFORMATION

COPY

ASSIGNMENT INFORMATION

Assignee Name:: Creighton University
Street of Mailing Address:: 2500 California Plaza
City of Mailing Address:: Omaha
State or Province of Mailing Address:: NE
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 68178

OCT 17 2007

Docket No: 180.00120101

DECLARATION

I, Zhao Yi Wang, the sole inventor of the invention claimed, declare that: (1) my citizenship and residence/mailling address are indicated below; (2) I have reviewed and understand the contents of the specification identified below, including the claims, as amended by any amendment specifically referred to herein, (3) I believe that I am the original and first inventor of the subject matter in

ESTROGEN RECEPTORS AND METHODS OF USE

International Filing Date: 10 March 2005

COPY
Serial No.: 10/591,199

described and claimed therein and for which a patent is sought; and (4) I hereby acknowledge my duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below, or §365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed:

- a. ☒ no such applications have been filed.
b. ☐ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC §119(a)-(d), §365(a), and/or §365(b)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

ALL FOREIGN APPLICATIONS, IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

Title 37, Code of Federal Regulations, §1.56 is reproduced on the attached page.

RECEIVED
CENTRAL FAX CENTER

Page 2 of 3

OCT 17 2007

Declaration

Serial No. 10/591,199

Confirmation No. 4302

Filing Date: 10 March 2005

Title: ESTROGEN RECEPTORS AND METHODS OF USE

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

- a. ☐ no such applications have been filed.
b. ☒ such applications have been filed as follows:

COPY

PROVISIONAL APPLICATION(S), IF ANY, UNDER 35 USC §119(e)	
APPLICATION NUMBER	DATE OF FILING (day, month, year)
60/552,067	10 March 2004
60/643,469	13 January 2005

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America, listed below.

- a. ☒ no such applications have been filed.
b. ☐ such applications have been filed as follows:

APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

The undersigned declares further that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, I pray that Letters Patent be granted to me for the invention described and claimed in the specification identified above and I hereby subscribe my name to the foregoing specification, claims, and Declaration on the date indicated below.

Name: Zhao Yi Wang

Citizenship: US

Address: 10005 South 11th Street, Bellevue, NE 68123, US

Date

5/11/07

Declaration

Serial No. 10/591,199

Confirmation No. 4302

Filing Date: 10 March 2005

Title: ESTROGEN RECEPTORS AND METHODS OF USE

Page 3 of 3

COPY**§ 1.56 Duty to disclose information material to patentability.**

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
- (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

(e) In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

**RECEIVED
CENTRAL FAX CENTER**

OCT 17 2007

PATENT
Docket No. 180.00120201

5 ESTROGEN RECEPTORS AND METHODS OF USE

CONTINUING APPLICATION DATA

COPY

This application claims the benefit of U.S. Provisional Application
Serial No. 60/552,067, filed 10 March 2004, and 60/643,469, filed 13 January
10 2005, each of which is incorporated by reference herein.

Government Funding

The invention described herein was developed with support from the
15 Department of Health and Human Services under Grant Number CA84328. The
U.S. Government has certain rights in the invention.

BACKGROUND OF THE INVENTION

20 Estrogen is a generic term for steroid compounds that are formed in the
ovary, the testis, and possibly the adrenal cortex. Examples of estrogens and
compounds having estrogen activity include diethylstilbestrol, fosfestrol,
hexestrol, polyestradiol phosphate, broparoestrol, chlorotrianisene, dienestrol,
diethylstilbestrol, methestrol, colpormon, equilenin, equilin, estradiol, estriol,
25 estrone, ethinyl estradiol, mestranol, mexestrol, quinestradiol and quinestrol.
Estrogens regulate diverse physiological processes in reproductive tissues and in
mammary, cardiovascular, bone, liver, and brain tissues. Estrogens are also
used in oral contraceptives. Other uses for estrogens include the relief of the
discomforts of menopause, inhibition of lactation, and treatment of
30 osteoporosis, threatened abortion, and various functional ovarian disorders.
Anti-estrogens are used to treat metastatic breast carcinoma and advanced
prostate cancer.